Anti-Human CA9 Recombinant Antibody (Iodine (124I) Girentuximab) (CAT#: TAB-H43)

Recombinant Chimeric antibody to Human CA9. The drug candidate REDECTANE® (INN: 124I-Girentuximab) is based on an antibody and is being developed for the pre-surgical diagnosis of clear cell Renal Cell Cancer. REDECTANE® is the radioactively labelled form of the antibody Girentuximab. The monoclonal antibody Girentuximab binds specifically to a protein structure on the cell surface of malignant tumour cells. This protein structure, called Carbonic anhydrase IX (also CA-IX, MN or G250 antigen) is found on over 90 % of clear cell renal cell carcinomas, but not on normal renal tissue.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 G250 (Girentuximab) monoclonal antibody (MAb) binding properties ‑ domain specificity.

Figure 1 G250 (Girentuximab) monoclonal antibody (MAb) binding properties ‑ domain specificity.

The target domain of the parental murine mG250 Mab was determined by ELISA.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international journal of oncology, 45(6), 2455-2467.

IP

Figure 2 G250 (Girentuximab) monoclonal antibody (MAb) binding properties ‑ domain specificity.

Figure 2 G250 (Girentuximab) monoclonal antibody (MAb) binding properties ‑ domain specificity.

The CA domain specificity of G250 MAb was confirmed by immunoprecipitation of the full‑length human carbonic anhydrase gene (CA9) and its deletion variants from biotinylated cell extracts with G250 Mab as well as with M75 and V/10 Mabs as controls.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international journal of oncology, 45(6), 2455-2467.

ELISA

Figure 3 Monoclonal antibody (MAb) specificly binds to target.

Figure 3 Monoclonal antibody (MAb) specificly binds to target.

The competitive ELISA was performed with the biotin-labeled G250 competing for binding to CA IX antigen from MDCK-CA9 cell extract against increasing concentrations of the simultaneously added non-labeled CA IX-specific antibodies.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jonal of oncology, 45(6), 2455-2467.

IP

Figure 4 G250 monoclonal antibody (MAb) binding properties - antigen/isoform specificity.

Figure 4 G250 monoclonal antibody (MAb) binding properties - antigen/isoform specificity.

Ability of mG250 MAb to recognize the full-length CA (FL) and its ectodomain (ECD), but not the alternatively spliced variant (hAS) was demonstrated by immunoprecipitation using the extracts and media from CGL3 cells naturally expressing CA and from the transfected MDCK cells (MDCK-hAS), followed by the western blotting with the M75 MAb.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jol of oncology, 45(6), 2455-2467.

IF

Figure 5 cG250 monoclonal antibody (MAb) binding in presence of carbonic anhydrase (CA) inhibitor homosulfanilamide.

Figure 5 cG250 monoclonal antibody (MAb) binding in presence of carbonic anhydrase (CA) inhibitor homosulfanilamide.

cG250 binding to CGL3 cells in absence and presence of the inhibitor was also visualized by immunofluorescence.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jol of oncology, 45(6), 2455-2467.

IF

Figure 6 G250 monoclonal antibody (MAb) internalization: co-localization with carbonic anhydrase protein (CA IX) and effects of hypoxia, pH and cell density.

Figure 6 G250 monoclonal antibody (MAb) internalization: co-localization with carbonic anhydrase protein (CA IX) and effects of hypoxia, pH and cell density.

cG250-CA IX co-localization was evaluated in normoxic MDCK-CA9 cells subjected to different cG250 internalization periods.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international jol of oncology, 45(6), 2455-2467.

Inhib

Figure 7 In vivo anticancer effects of mG250 monoclonal antibody (MAb) on tumour growth and serum levels of shed carbonic anhydrase protein (CA IX) ectodomain (ECD).

Figure 7 In vivo anticancer effects of mG250 monoclonal antibody (MAb) on tumour growth and serum levels of shed carbonic anhydrase protein (CA IX) ectodomain (ECD).

Graph illustrating volumes of tumours grown from subcutaneously xenografted HT-29 cells in mice subjected to either immediate or delayed onset of treatment with mG250 MAb in comparison to non-treated controls (n=20 per group) as calculated from caliper measurements.

Zatovicova, M., Jelenska, L., Hulikova, A., Ditte, P., Ditte, Z., Csaderova, L., ... & Pastorek, J. (2014). Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non‑renal cancer model. international joof oncology, 45(6), 2455-2467.


Specifications

  • Host Species
  • undefined
  • Derivation
  • Chimeric
  • Type
  • IgG1 - kappa
  • Specificity
  • CA9 (carbonic anhydrase IX, CAIX, MN, G250) [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, IF, Inhib
  • Trade name
  • redectane
  • CAS
  • 953400-68-5
  • Generic Name
  • iodine (124I) girentuximab
  • UNII
  • 539B57DFJF
  • MW
  • 146.5 kDa
  • Related Disease
  • Kidney tumours

Product Property

  • Purity
  • Purity >95% by SDS-PAGE.

Applications

  • Application Notes
  • The Human CA9 antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Immunoprecipitation, Immunofluorescence, Inhibition.

Target

  • Alternative Names
  • iodine (124I) girentuximab;redectane;953400-68-5;CA9;carbonic anhydrase IX;carbonic anhydrase 9;CAIX;carbonic dehydratase;MN;RCC associated protein G250;pMW1;CA-IX;P54/58N;membrane antigen MN;carbonate dehydratase IX;RCC-associated antigen G250;RCC-associ

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "CA9"

Chimeric Antibody

CAT Product Name Application Type
TAB-707 Anti-CAIX/CA9 Recombinant Antibody (Girentuximab) WB, FuncS, IF, Neut, ELISA, FC, IP IgG1 - kappa

Human Antibody

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0427 Hi-Affi™ Rabbit Anti-CA9 Recombinant Antibody (clone DS427AB) IHC-P, WB Rabbit IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H43 Afuco™ Anti-CA9 ADCC Recombinant Antibody (Girentuximab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H43. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare